Novo Nordisk announces expansion of Hillerød API manufacturing facility
![](/46/pdcnewsitem/12/10/82/CPHI%20images%20(43).png)
Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.
Novo Nordisk have announced on June 12, 2023 that they are to invest DKK 15.9 billion kr. for the expansion of their API manufacturing facility in Denmark for products that treat serious chronic diseases, such as diabetes.
The current production facility, located in Hillerød, Denmark, will benefit from the investment with increased production capacity and enable the Danish pharmaceutical company to meet market demands in the future regarding drug products for chronic diseases. The facility will particularly develop Novo Nordisk’s ability to develop a clinical late-phase product portfolio in the future.
An additional 65,000 m2 will be added to design a multi-product facility and house state-of-the-art technology to ensure flexibility in accommodating new processes. The new facility will be geared towards delivering high-quality drug products compliant with environmental sustainability regulations through the use of compact and optimal process flow that reduce the consumption of water and energy. Construction has already begun, with the facility to start producing APIs by 2029, creating 340 new jobs within the region.
Henrik Wulff, Executive VP of Product Supply, Quality & IT at Novo Nordisk, highlighted the importance of the investment and the healthcare opportunities that can be provided with the right infrastructure: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” he commented. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”
Source: Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark [Accessed June 12, 2023] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166116
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance